Table 3: The activity of the component #1 of the B. subtilis 534 antibacterial complex against clinical isolates of A. baumannii.
| Clinical isolates, ## | Growth inhibition zones of component #1, mm | The susceptibility/resistance of clinical isolates against 15 medical antibiotics* | ||
| R | I | S | ||
| 1630 | 9 | 15 | 0 | 0 |
| 1839 | 9 | 14 | 14 | 0 |
| 2050 | 9 | 15 | 0 | 0 |
| 2455 | 8 | 15 | 0 | 0 |
| 2617 | 12 | 15 | 0 | 0 |
| 3037 | 10 | 14 | 1(GM) | 0 |
| 3050 | 0 | 13 | 2(GM, PIP) | 0 |
| 3122 | 7 | 15 | 0 | 0 |
| 3164 | 0 | 13 | 2(GM, LVX) | 0 |
| 0 | 7 | 15 | 0 | |
| 0 | 8 | 15 | 0 | |
| 3238 | 7 | 12 | 3(GM, FEP, SAM) | 0 |
| 3255 | Trace*** | 15 | 0 | 0 |
| 3275 | Trace*** | 3 | 5(PIP, GM, CRO) | 7(AN, FEP, SAM, CIP, LVX, MEM, NN) |
| 3613 | Trace*** | 15 | 0 | 0 |
| 4006 | Trace*** | 15 | 0 | 0 |
| 4066 | Trace*** | 15 | 0 | 0 |
| 4074 | Trace*** | 15 | 0 | 0 |
| 4165 | 9 | 13 | 1(MEM) | 1(TE) |
| 4200 | Trace*** | 15 | 0 | 0 |
| 4315 | Trace*** | 15 | 0 | 0 |
| 4354 | 8 | 15 | 0 | 0 |
| 4372 | 0 | 15 | 0 | 0 |
| 4374 | 0 | 13 | 1(MEM) | 1(TE) |
*Antibiotics: AN: Amikacin; SAM: Ampicillin/Sulbactam; GM: Gentamicin; IPM: Imipenem; LVX: Levofloxacin; MEM: Meropenem; PIP: Piperacillin; TE: Tetracycline; NN: Tobramycin; SXT: Trimethoprim/Sulfamethoxazole; FEP: Cefepime; CTX: Cefotaxime; CAZ: Ceftazidime; CRO: Ceftriaxone; CIP: Ciprofloxacin; R: Resistance; I: Intermediate susceptibility; S: Susceptibility.
***"Trace" - The thickness of the ring of the growth inhibition zone around the hole in agar medium with the sample which is tested for antimicrobial activity does not exceed 1 mm.